tbuckley/cabot-search huggingface dataset:
Evaluation of niraparib 200 mg/d as maintenance therapy in recurrent ovarian cancer and associated thrombocytopenia in a real-world US setting
Authors: P. Thaker, K. Travers, C. Karki, R.P. Patel, C. Krebsbach, B. Harrow, S.N. Westin
Journal: Annals of Oncology (2019)
Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy
Authors: Y. Loriot, A. Balar, R. de Wit, J.A. Garcia, P. Grivas, N. Matsubara, T.L. Frenkl, E. Sbar, X.C. Jia, T. Fouad, A.O. Siefker-Radtke
Journal: Annals of Oncology (2019)
Lung Ultrasound in Acute Heart Failure
Authors: Elke Platz, Ross T. Campbell, Brian Claggett, Eldrin F. Lewis, John D. Groarke, Kieran F. Docherty, Matthew M.Y. Lee, Allison A. Merz, Montane Silverman, Varsha Swamy, Moritz Lindner, Jose Rivero, Scott D. Solomon, John J.V. McMurray
Journal: JACC Heart Failure (2019)
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Authors: M. Zuazo, H. Arasanz, M J García Granda, A.I. Bocanegra, G. Fernández-Hinojal, M. Gato-Cañas, M Martínez Aguillo, B Hernández Marín, L. Teijeira, I Morilla Ruiz, R. Vera, G. Kochan, D. Escors
Journal: Annals of Oncology (2019)
A Window Into the Soul
Authors: Ersilia M. DeFilippis
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse
Authors: Yishai Ofran, Chezi Ganzel, Shimrit Harlev, Ilana Slouzkey, Ofrat Beyar Katz, Michal Hayun, Mira Kharit, Jacob M. Rowe, Avraham Frisch
Journal: Blood (2018)
Metformin for Type 2 Diabetes—Reply
Authors: James Flory, Kasia Lipska
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peptic ulcer disease
Authors: Emma Sverdén, Lars Agréus, Jason M Dunn, Jesper Lagergren
Journal: BMJ (2019)

### What you need to know

Peptic ulcer disease presents with gastrointestinal symptoms similar to dyspepsia and can be difficult to distinguish clinically. It can have potentially serious complications such as bleeding or perforation, with a high risk of mortality.1 Optimal treatment with proton pump inhibitors (PPIs) facilitates healing and can prevent complications and recurrence.

Observational studies and surveys among healthcare providers report that adherence to evidence based treatment guidelines is often poor.23456789 This results in inadequate treatment and overuse of PPIs. Increasingly, antibiotic resistance has affected the choice of eradication regimen for Helicobacter pylori infection, the main risk factor. In this Clinical Update, we review the epidemiology and management of peptic ulcer disease for non-specialists to guide prompt diagnosis and appropriate treatment.

Peptic ulcer disease is often defined as a mucosal break greater than 3-5 mm in the stomach or duodenum with a visible depth. It is therefore an endoscopic diagnosis in contrast to dyspepsia, which is a clinical diagnosis based on symptoms alone. Peptic ulcer disease results from an imbalance between factors that protect the mucosa of the stomach and duodenum, and factors that cause damage to it (fig 1). …
Abstract 12131: Chronotropic Incompetence is Not Associated With Prognosis in Heart Failure Patients With Preserved Ejection Fraction and Atrial Fibrillation
Authors: Takamasa Sato, Akiomi Yoshihisa, Takafumi Ishida, Yasuchika Takeishi
Journal: Circulation (2017)

Introduction: Both resting heart rate (HR) and chronotropic incompetence (CI) are independent prognostic markers in individuals with sinus rhythm (SR) and reduced left ventricular ejection fraction...
Variation in Prescription Drug Prices by Retail Pharmacy Type
Authors: Jing Luo, Martin Kulldorff, Ameet Sarpatwari, Ajinkya Pawar, Aaron S. Kesselheim
Journal: Annals of Internal Medicine (2019)

Cash prices for prescription drugs vary widely in the United States.To describe cash price variation by retail pharmacy type for 10 generic and 6 brand-name drugs throughout the United States and stratified by ZIP code.Cross-sectional study.Drug pricing data from GoodRx, an online tool for comparing drug prices, representing more than 60 000 U.S. pharmacies (fall 2015).Cash prices for a 1-month supply of generic and brand-name drugs were ascertained. Stratified by ZIP code, relative cash prices for groups of generic and brand-name drugs were estimated for big box, grocery-based, small chain, and independent pharmacies compared with a reference group of large chain pharmacies.Across 16 325 ZIP codes, 68 353 unique pharmacy stores contributed cash prices. When stratified by 5-digit ZIP code, the relative cash prices for generic drugs at big box, grocery-based, small chain, and independent pharmacies compared with those at large chain pharmacies were 0.52 (95% CI, 0.51 to 0.53), 0.82 (CI, 0.81 to 0.83), 1.51 (CI, 1.45 to 1.56), and 1.61 (CI, 1.58 to 1.64), respectively. The relative cash prices for brand-name drugs were 0.97 (CI, 0.96 to 0.97), 1.00 (CI, 0.99 to 1.00), 1.06 (CI, 1.05 to 1.08), and 1.03 (CI, 1.02 to 1.04), respectively.Results may not reflect current drug prices and do not account for point-of-sale discounts or price matching that may be offered by smaller pharmacies.Compared with large chains, independent pharmacies and small chains had the highest cash prices for generic drugs and big box pharmacies the lowest. Relative differences in cash prices for brand-name drugs were modest across types of retail pharmacies.Arnold Ventures.
Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
Authors: Y. Yoshida, T. Yamada, H. Matsuoka, K. Hirata, H. Kuramochi, C. Kosugi, M. Takahashi, A. Fukazawa, H. Sonoda, A. Matsuda, T. Watanabe, M. Koizumi, N. Aisu, S. Hasegawa, H. Yoshida, K. Sakamoto, H. Ishida, K. Koda
Journal: Annals of Oncology (2019)
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Authors: A. Vogel, V. Sahai, A. Hollebecque, G. Vaccaro, D. Melisi, R. Al-Rajabi, A.S. Paulson, M.J. Borad, D. Gallinson, A.G. Murphy, D.-Y. Oh, E. Dotan, D.V. Catenacci, E. Van Cutsem, C.F. Lihou, H. Zhen, L. Féliz, G.K. Abou-Alfa
Journal: Annals of Oncology (2019)
A Novel Dendritic Cell Population Generated by Fusing Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-21 Induces Tumor-Antigen Specific Immunity
Authors: Patrick Williams, Manaf Bouchentouf, Moutih Rafei, Raphaelle Romieu-Mourez, Hsiang-Chuan (Jeremy) Hsieh, Marie-Noelle Boivin, Shala Yuan, Kathy-Ann Forner, Elena Birman, Jacques Galipeau
Journal: Blood (2010)
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study
Authors: Maaike Buskermolen, Dayna R Cenin, Lise M Helsingen, Gordon Guyatt, Per Olav Vandvik, Ulrike Haug, Michael Bretthauer, Iris Lansdorp-Vogelaar
Journal: BMJ (2019)

To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates.Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies.
Ultrasound and Microbubble-targeted Delivery of a microRNA Inhibitor to the Heart Suppresses Cardiac Hypertrophy and Preserves Cardiac Function
Authors: Jonathan A. Kopechek, Charles F. McTiernan, Xucai Chen, Jianhui Zhu, Maureen Mburu, Rafey Feroze, Daniel A. Whitehurst, Linda Lavery, Jissy Cyriac, Flordeliza S. Villanueva
Journal: Theranostics (2019)

MicroRNAs (miRs) are dysregulated in pathological left ventricular hypertrophy.AntimiR inhibition of miR-23a suppressed hypertension-induced cardiac hypertrophy in preclinical models, but clinical translation is limited by a lack of cardiac-targeted delivery systems.Ultrasound-targeted microbubble cavitation (UTMC) utilizes microbubbles as nucleic acid carriers to target delivery of molecular therapeutics to the heart.The objective of this study was to evaluate the efficacy of UTMC targeted delivery of antimiR-23a to the hearts of mice for suppression of hypertension-induced cardiac hypertrophy.Methods: Cationic lipid microbubbles were loaded with 300 pmol negative control antimiR (NC) or antimiR-23a.Mice received continuous phenylephrine infusion via implanted osmotic minipumps, then UTMC treatments with intravenously injected antimiR-loaded microbubbles 0, 3, and 7 days later.At 2 weeks, hearts were harvested and miR-23a levels were measured.Left ventricular (LV) mass and function were assessed with echocardiography.Results: UTMC treatment with antimiR-23a decreased cardiac miR-23a levels by 41 ± 8% compared to UTMC + antimiR-NC controls (p < 0.01).Furthermore, LV mass after 1 week of phenylephrine treatment was 17 ± 10% lower following UTMC + antimiR-23a treatment compared to UTMC + antimiR-NC controls (p = 0.02).At 2 weeks, fractional shortening was 23% higher in the UTMC + antimiR-23a mice compared to UTMC + antimiR-NC controls (p < 0.01).Conclusions: UTMC is an effective technique for targeted functional delivery of antimiRs to the heart causing suppression of cardiac hypertrophy and preservation of systolic function.This approach could represent a revolutionary therapy for patients suffering from pathological cardiac hypertrophy and other cardiovascular conditions.
Abstract 13401: Clinical Outcome after Transfemoral Aortic Valve Replacement in Patients with Low-Gradient Aortic Stenosis in Local Anesthesia
Authors: Suzanne Fateh-Moghadam, Karin Mueller, Patrik Htun, Martin Steeg, Iris Mueller, Begir Sutaj, Rezo Jobenadze, Meinrad Gawaz, wolfgang bocksch
Journal: Circulation (2012)

Objectives The aim of this study was to evaluate clinical outcome after CoreValve implantation in patients (pts) with low-gradient aortic stenosis (LGAS). We were especially interested in the 30 da...
Malignant non-adrenal paraganglioma (mPara) and adrenal pheochromocytoma (mPheo) a comparative comprehensive genomic profiling (CGP) study
Authors: G. Bratslavsky, E.S. Sokol, A. Necchi, O. Shapiro, J. Jacob, N. Liu, J.A. Elvin, J.-A. Vergilio, J.K. Killian, N. Ngo, D. Lin, S. Ramkissoon, E. Severson, S.M. Ali, A.B. Schrock, J. Chung, P. Reddy, B.M. Alexander, V.A. Miller, J.S. Ross
Journal: Annals of Oncology (2019)
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial
Authors: G. Griguolo, M.V. Dieci, L. Paré, F. Miglietta, D.G. Generali, A. Frassoldati, G. Bisagni, F. Piacentini, E. Tagliafico, K. Cagossi, G. Ficarra, A. Prat, P.F. Conte, V. Guarneri
Journal: Annals of Oncology (2019)
Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Authors: D. Mavroudis, C. Papadaki, A. Monastirioti, K. Rounis, G. Stoupis, D. Makrakis, M. Markaki, K. Kalbakis, S. Agelaki
Journal: Annals of Oncology (2019)
Acquired vincristine-resistance is accompanied by altered cell cycle distribution and downregulation of the mitotic regulator DNA topoisomerase II alpha.
Authors: Andrzej M. Skladanowski, Marie-George Come, Alexandre E. Escargeuil, Annette K. Larsen
Journal: Cancer Research (2004)

3075  Microtubule inhibitors are cell-cycle specific agents with preferential cytotoxicity toward mitotic cells. To determine if development of vincristine-resistance is accompanied by altered cell cycle progression, the cell cycle distribution of parental HL-60 and CEM cells were compared with their vincristine-resistant variants, HL-60/Vinc and CEM/VCR, respectively. No alterations were observed between parental and resistant cells with regard to cell doubling time and the fraction of S phase cells. In contrast, the fraction of cells in the G2 phase of the cell cycle had doubled in both resistant cells lines. Expression levels of major mitotic regulators including Cdc2 kinase, p21, 14-3-3 sigma, 14-3-3 epsilon and topoisomerase II alpha were determined by Western blot analysis. The results show no detectable changes for Cdc2 kinase, p21 and the two 14-3-3 forms whereas topoisomerase IIalpha is downregulated to about one-third of the initial levels in both vincristine-resistant cell lines. In comparison, no differences were observed for the other topoisomerase II isoform, topoisomerase II beta, that is dispensable for mitosis. Downregulation of topoisomerase II alpha was accompanied by a strong decrease in the association of the enzyme with mitotic chromosomes, decreased catalytic activity and cross-resistance to topoisomerase II inhibitors. We have recently shown that topoisomerase II alpha is required for the recruitment of the mitotic Cdc2 kinase to the chromatin and is accompanied by early chromosome condensation and mitotic onset (Escargueil et al., FASEB J 15: 2288, 2001). The results presented here suggest that downregulation of topoisomerase II alpha may delay mitotic onset thereby maintaining cells in a cell cycle phase where they are less sensitive to microtubule inhibitors. Our results reveal an unexpected role of topoisomerase II alpha in the celullar resistance to microtubule inhibitors.
Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Authors: James K McCloskey, Genique Stanislaus, Jamie L. Koprivnikar, Tracy Andrews, Jones Elizabeth, Danielle Marcotulli, Grace Perry, Stuart L. Goldberg, Stefan Faderl
Journal: Blood (2017)
Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Authors: M. Droz Dit Busset, S. Braun, B. El-Rayes, W.P. Harris, N. Damjanov, G. Masi, L. Rimassa, S. Bhoori, M. Niger, N. Personeni, F. Braiteh, S. Lonardi, M. Engelhardt, M. Saulay, B. Schwartz, W.L. Shaib, V. Mazzaferro, K.P. Papadopoulos
Journal: Annals of Oncology (2019)
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Authors: C. Morizane, T. Okusaka, J. Mizusawa, H. Katayama, M. Ueno, M. Ikeda, M. Ozaka, N. Okano, K. Sugimori, A. Fukutomi, H. Hara, N. Mizuno, H. Yanagimoto, K. Wada, K. Tobimatsu, K. Yane, S. Nakamori, H. Yamaguchi, A. Asagi, S. Yukisawa, Y. Kojima, K. Kawabe, Y. Kawamoto, R. Sugimoto, T. Iwai, K. Nakamura, H. Miyakawa, T. Yamashita, A. Hosokawa, T. Ioka, N. Kato, K. Shioji, K. Shimizu, T. Nakagohri, K. Kamata, H. Ishii, J. Furuse
Journal: Annals of Oncology (2019)
Maf1 ameliorates cardiac hypertrophy by inhibiting RNA polymerase III through ERK1/2
Authors: Yu Sun, Cong Chen, Ruicong Xue, Yan Wang, Bin Dong, Jiayong Li, Chen Chen, Jingzhou Jiang, Wendong Fan, Zhuomin Liang, Huiling Huang, Rong Fang, Gang Dai, Youchen Yan, Tiqun Yang, Xiangxue Li, Zhan-Peng Huang, Yugang Dong, Chen Liu
Journal: Theranostics (2019)

Rationale: An imbalance between protein synthesis and degradation is one of the mechanisms of cardiac hypertrophy.Increased transcription in cardiomyocytes can lead to excessive protein synthesis and cardiac hypertrophy.Maf1 is an RNA polymerase III (RNA pol III) inhibitor that plays a pivotal role in regulating transcription.However, whether Maf1 regulates of cardiac hypertrophy remains unclear.Methods: Cardiac hypertrophy was induced in vivo by thoracic aortic banding (AB) surgery.Both the in vivo and in vitro gain-and loss-of-function experiments by Maf1 knockout (KO) mice and adenoviral transfection were used to verify the role of Maf1 in cardiac hypertrophy.RNA pol III and ERK1/2 inhibitor were utilized to identify the effects of RNA pol III and ERK1/2.The possible interaction between Maf1 and ERK1/2 was clarified by immunoprecipitation (IP) analysis.Results: Four weeks after surgery, Maf1 KO mice exhibited significantly exacerbated AB-induced cardiac hypertrophy characterized by increased heart size, cardiomyocyte surface area, and atrial natriuretic peptide (ANP) expression and by exacerbated pulmonary edema.Also, the deficiency of Maf1 causes more severe cardiac dilation and dysfunction than wild type (WT) mice after pressure overload.In contrast, compared with adenoviral-GFP injected mice, mice injected with adenoviral-Maf1 showed significantly ameliorated AB-induced cardiac hypertrophy.In vitro study has demonstrated that Maf1 could significantly block phenylephrine (PE)-induced cardiomyocyte hypertrophy by inhibiting RNA pol III transcription.However, application of an RNA pol III inhibitor markedly improved Maf1 knockdown-promoted cardiac hypertrophy.Moreover, ERK1/2 was identified as a regulator of RNA pol III, and ERK1/2 inhibition by U0126 significantly repressed Maf1 knockdown-promoted cardiac hypertrophy accompanied by suppressed RNA pol III transcription.Additionally, IP analysis demonstrated that Maf1 could directly bind ERK1/2, suggesting Maf1 could interact with ERK1/2 and then inhibit RNA pol III transcription so as to attenuate the development of cardiac hypertrophy.Conclusions: Maf1 ameliorates PE-and AB-induced cardiac hypertrophy by inhibiting RNA pol III transcription via ERK1/2 signaling suppression.
Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Authors: P. Spiliopoulou, S. Spear, S. Dowson, S. Mason, K. Blyth, M. Fuchter, B. Brown, I.A. McNeish
Journal: Annals of Oncology (2019)
CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
Authors: R. de Wit, G. Kramer, J.-C. Eymard, J.S. de Bono, C.N. Sternberg, K. Fizazi, B. Tombal, C. Wülfing, A. Bamias, J. Carles, R. Iacovelli, B. Melichar, A. Sverrisdottir, C. Theodore, S. Feyerabend, C. Helissey, P. Picard, A. Ozatilgan, C. Geffriaud-Ricouard, D. Castellano
Journal: Annals of Oncology (2019)
Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice
Authors: I. Petak, C. Hegedus, E. Várkondi, Z. Farkas, D. Tihanyi, R. Dóczi, D. Mathiasz, E. Lengyel, G. Pajkos, R. Schwab, J. Deri, I. Vályi-Nagy
Journal: Annals of Oncology (2019)
Master checkpoint Cbl-b inhibition: Anti-tumour efficacy in a murine colorectal cancer model following siRNA-based cell therapy
Authors: K. Thell, M. Urban, J. Harrauer, I. Haslinger, M. Kuttke, J.S. Brunner, A. Vogel, G. Schabbauer, J. Penninger, A. Gaweco
Journal: Annals of Oncology (2019)
Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumours
Authors: A.A. Davis, W. Iams, D. Chan, M.S. Oh, R.W. Lentz, N. Peterman, A. Robertson, A. Shah, R. Srivas, N. Lambert, T. Wilson, P. George, B. Wong, J. Close, H. Wood, A. Tezcan, J.C. Spinosa, H. Tezcan, Y.K. Chae
Journal: Annals of Oncology (2019)
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
Authors: E.A. Rozeman, A.M. Menzies, O. Krijgsman, E.P. Hoefsmit, B.A. van de Wiel, K. Sikorska, T.M. Van, H. Eriksson, C. Bierman, M. Gonzalez, K. Shannon, A. Broeks, R. Kerkhoven, A.J. Spillane, R.P. Saw, A.C.J. van Akkooi, R.A. Scolyer, J. Hansson, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2019)
Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: A comparison of RECIST 1.1, RANO and iRANO criteria
Authors: E. Le Rhun, F. Wolpert, M. Fialek, P. Devos, N. Andratschke, N. Reyns, R. Dummer, L. Mortier
Journal: Annals of Oncology (2019)